Zhao Linfang, Yang Xiaohui, Liu Chang, Yu Weihua, Cao Xiuzhu, Li Xiangyun, Wang Jie, Zhuang Yiyu
Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, 310016, China.
Wenzhou Medical University, Wenzhou, China.
Sci Rep. 2025 Aug 20;15(1):30534. doi: 10.1038/s41598-025-12551-0.
Bariatric surgery is an effective treatment for moderate-to-severe obesity, however, reliable vascular access during the perioperative period remains a challenge in this population. This study compared the safety and efficacy of midline catheters (MCs) and long peripheral catheters (LPCs) in patients who underwent bariatric surgery. This single-blind, randomised controlled trial was conducted at a tertiary acute hospital between September 2023 and January 2024. A totol of 224 patients were assigned to receive either MC or LPC. The primary outcome was catheter failure; secondary outcomes included insertion attempts, time to insert the device, indwelling time, complications, requirements for additional vascular access devices, and patient satisfaction. The incidence of catheter failure was significantly lower in the MCs group (10.71%) than in the LPCs group (20.54%; odds ratio [OR] 0.46; 95% confidence interval [CI], 0.22-0.99; P = 0.043). Additionally, MCs had longer median indwelling times (7 d vs. 5 d; P < 0.001), fewer complications (13.39% vs. 27.68%; OR 0.40; 95% CI, 0.20-0.80; P = 0.008), and required fewer additional devices (4.46% vs. 16.07%; OR 0.24; 95% CI, 0.09-0.68; P = 0.004). These findings suggest that MCs are a superior choice for vascular access devices in patients undergoing bariatric surgery.Trial registration: Trial registered at ClinicalTrials.gov (NCT06031545 11/09/2023).
减肥手术是治疗中重度肥胖的有效方法，然而，这一人群围手术期可靠的血管通路仍然是一项挑战。本研究比较了减肥手术患者中线导管（MCs）和外周长导管（LPCs）的安全性和有效性。这项单盲随机对照试验于2023年9月至2024年1月在一家三级急症医院进行。总共224名患者被分配接受MC或LPC。主要结局是导管失败；次要结局包括插入尝试、插入设备的时间、留置时间、并发症、额外血管通路设备的需求以及患者满意度。MCs组的导管失败发生率（10.71%）显著低于LPCs组（20.54%；优势比[OR]0.46；95%置信区间[CI]，0.22 - 0.99；P = 0.043）。此外，MCs的中位留置时间更长（7天对5天；P < 0.001），并发症更少（13.39%对27.68%；OR 0.40；95% CI，0.20 - 0.80；P = 0.008），并且需要的额外设备更少（4.46%对16.07%；OR 0.24；95% CI，0.09 - 0.68；P = 0.004）。这些发现表明，MCs是减肥手术患者血管通路设备的更佳选择。试验注册：该试验在ClinicalTrials.gov注册（NCT06031545 2023年9月11日）。
